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Attempts to identify genetic contributors to human meiotic nondisjunction have met with little, if any, success.
Thus, recent reports linking Down syndrome to maternal polymorphisms at either of two folatemetabolismenzymes,
methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR), have generated con-
siderable interest. In the present report, we asked whether variation at MTHFR (677CrT) or MTRR (66ArG)
might be associated with human trisomies other than trisomy 21. We analyzed maternal polymorphisms atMTHFR
and MTRR in 93 cases of sex-chromosome trisomy, 44 cases of trisomy 18, and 158 cases of autosomal trisomies
2, 7, 10, 13, 14, 15, 16, 18, or 22, and compared the distributions of genotypes to those of control populations.
We observed a significant increase in the MTHFR polymorphism in mothers of trisomy 18 conceptuses but were
unable to identify any other significant associations. Overall, our observations suggest that, at least for the sex
chromosomes and for a combined set of autosomal trisomies, polymorphisms in the folate pathway are not a
significant contributor to human meiotic nondisjunction.
Since the identification of the first human trisomy, 140
years ago, many attempts have been made to elucidate
factors that influence the rate of meiotic nondisjunction
in our species. These efforts have been remarkably un-
successful; aside from the well-established association
between increasing maternal age and trisomy, no etio-
logical factor has been convincingly linked to human
nondisjunction (Abruzzo and Hassold 1995).
Given this background, recent observations of a link
between trisomy 21 and maternal polymorphisms in the
folate pathway were greeted with considerable excite-
ment (Rubin 1999). In an initial report, James et al.
(1999) compared the frequency of CrT mutations at
nucleotide 677 in the enzyme methylenetetrahydrofolate
reductase (MTHFR [MIM 236250]) between mothers
of individuals with Down syndrome (DS) and age-
matched control females. The 677CrT mutation affects
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both folate metabolism and cellular methylation reac-
tions and is a known risk factor for neural tube defects
(van der Put et al. 1998). James et al. (1999) hypothe-
sized that aberrant DNA methylation as a result of ab-
normal folate metabolism due to the mutation might
increase the likelihood of meiotic nondisjunction, thus
making the mutation a risk factor for trisomy 21, as well
as for neural tube defects. In their analyses of 57 case
and 50 control women, they observed significant in-
creases in plasma homocysteine concentrations among
mothers of DS individuals, consistent with a functional
folate deficiency among these individuals. Further, they
found a highly significant increase in the proportion of
CT heterozygotes and TT mutant homozygotes among
the case mothers, consistent with a gene-nutrient effect
on chromosome 21 nondisjunction.
In a follow-up study (Hobbs et al. 2000), James and
colleagues expanded their study population to 157 case
and 144 control mothers, reexamined the association
between MTHFR polymorphisms and trisomy 21, and
analyzed maternal polymorphisms at a second gene in
the folate pathway, methionine synthase reductase
(MTRR [MIM 602568]); an ArG mutation at position
66 of MTRR has been linked to an increase in spina
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bifida (Wilson et al. 1999). Hobbs et al. (2000) con-
firmed the initial observations of a link betweenMTHFR
and trisomy 21 and found a highly significant increase
in GG mutant homozygotes at MTRR among DS moth-
ers. Furthermore, the combined presence of both mu-
tations appeared to increase the risk, since the highest
odds ratios were observed among women with either
CT or TT genotypes at MTHFR and a GG genotype at
MTRR—that is, among women having a “susceptible”
genotype at each locus.
Subsequently, another group has also linked MTRR
polymorphisms to trisomy 21 (O’Leary et al., in press).
Specifically, in an analysis of 48 mothers of individuals
with DS and 192 control mothers, they identified a
highly significant increase in the G allele among the case
mothers.
Taken together, these reports provide preliminary ev-
idence of a genetic component to human nondisjunction
which, if confirmed, would represent the first known
genetic contributor to meiotic chromosome malsegre-
gation in our species. Further, these results suggest the
possibility of relatively simple preventative strategies,
since dietary folate and vitamin B12 supplementation
might overcome the risk of nondisjunction associated
with the susceptible genotypes. The potential importance
of this association makes it essential that the original
observations on trisomy 21 be confirmed or refuted, and
that the possibility of an effect on nondisjunction of
other chromosomes be investigated. In the present re-
port, we summarize studies that address the latter issue,
specifically analyzing maternal folate-pathway poly-
morphisms in sex-chromosome trisomies and autosomal
trisomies 2, 7, 10, 13, 14, 15, 16, 18, and 22.
Study material was obtained from two centers that
have been actively engaged in analyses of the origin of
human trisomies, namely the Wessex Regional Genetics
Laboratory in Salisbury, England (“Wessex”) and the
Department of Genetics at Case Western Reserve Uni-
versity in Cleveland, OH (“Cleveland”). We analyzed
maternal DNA samples from trisomies that were known
to be maternal in origin (Fisher et al. 1993, 1995; Mac-
Donald et al. 1994; Zaragoza et al. 1994, 1998; Thomas
et al. 2001); a total of 311 such samples were available
for study. At Wessex, maternal DNA samples were avail-
able for 104 cases of sex-chromosome trisomy (70 cases
of 47,XXY and 34 cases of 47,XXX) and 45 cases of
trisomy 18. Virtually all cases of sex-chromosome tri-
somy involved live-born individuals, whereas cases of
trisomy 18 were ascertained from spontaneous abor-
tions, stillbirths, and therapeutic abortions; details re-
garding the ascertainment of the cases have been pro-
vided elsewhere (Fisher et al. 1993, 1995; MacDonald
et al. 1994). At Cleveland, maternal DNA samples were
available for 10 cases of trisomy 2, 10 cases of trisomy
7, 5 cases of trisomy 10, 27 cases of trisomy 13, 8 cases
of trisomy 14, 20 cases of trisomy 15, 66 cases of trisomy
16, and 16 cases of trisomy 22. With the exception of
four cases of trisomy 13, all trisomies were ascertained
from cytogenetic studies of spontaneous abortions (Za-
ragoza et al. 1994).
For controls, we utilized DNA samples being analyzed
at the Wessex or Cleveland centers for reasons unrelated
to those of the present study; whenever possible, these
involved mothers of chromosomally abnormal concep-
tuses who were known to have contributed the “right”
number of chromosomes. For example, at Wessex, con-
trols consisted of DNA samples from 57 mothers of
paternally derived cases of 47,XXY. Similarly, at Cleve-
land we used DNA samples from 25 mothers of andro-
genetic triploids, although we augmented this group
with an additional 24 samples from volunteer donors
being analyzed for other purposes. The racial compo-
sition of the Wessex and Cleveland study groups was
markedly different: at Wessex, all individuals were
white, whereas, at Cleveland, both case and control
groups consisted of ∼85% white and ∼15% black in-
dividuals. Since the mutant-allele frequencies atMTHFR
677 vary with race and ethnicity (Botto and Yang 2000)
and because the two centers analyzed different types of
trisomies, wemade no attempt to pool cases and controls
between centers. Instead, we made separate case-control
comparisons at each of the two study centers.
All case and control individuals were genotyped at
MTHFR and MTRR, using standard PCR-based meth-
odology (Hobbs et al. 2000). We obtained genotypes at
both loci for 280 of the 311 case individuals and for
100 of the 106 control individuals; for the remaining
individuals, we were able to score only one of the two
loci. We compared case and control allele frequencies at
MTHFR and MTRR separately for the two study cen-
ters, using standard goodness-of-fit tests. For each of the
two loci, we performed three different types of statistical
analyses: first, a comparison of allele frequencies be-
tween case and control individuals; second, a compar-
ison of the frequencies of the three genotypes among
case and control individuals; and, third, a comparison
of the frequencies of “susceptible” genotypes among
case and control individuals (i.e., at MTHFR, CT het-
erozygotes and TT homozygotes, and, at MTRR, GG
homozygotes). The distributions of genotypes for
MTHFR are provided in tables 1 and 2, and those for
MTRR are provided in tables 3 and 4. Additionally, the
tables provide the results of statistical tests comparing
the proportion of “susceptible” genotypes between con-
trols and each type of trisomy; other statistically signif-
icant results (i.e., case vs. control differences in allele
frequencies or in the proportions of the three genotypes)
are described below.
MTHFR: At Wessex, we found no obvious difference
in allele frequencies between mothers of 47,XXX/XXY
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Table 1
Maternal MTHFR Polymorphisms in Maternally Derived Cases of Sex Chromosome
Trisomy or Trisomy 18 and in Control Individuals
STUDY POPULATION






(CT OR TT)aCC CT TT
47,XXX or XXY ( )np 93 48 (51.6) 40 (43.0) 5 (5.4) ; NS2x p .01
Trisomy 18 ( )np 44 13 (29.5) 22 (50.0) 9 (20.5) ;2x p 5.00 P ! .05
Controls ( )np 56 29 (51.8) 22 (39.3) 5 (8.9) …
a NS p not significant.
Table 2
Maternal MTHFR Polymorphisms in Maternally Derived Cases of
Trisomies 2, 7, 10, 13, 14, 15, 16, or 22 and in Control Individuals
STUDY POPULATION







(CT OR TT)aCC CT TT
Trisomy:
2 2 7 1 ; NS2x p 2.20
7 6 2 2 ; NS2x p .66
10 2 2 1 ; NS2x p .06
13 14 11 2 ; NS2x p .25
14 2 5 1 ; NS2x p 1.23
15 10 10 0 ; NS2x p .99
16 30 27 5 ; NS2x p .07
22 7 9 0 ; NS2x p .02
Total ( )np 158 73 (46.2) 73 (46.2) 12 (7.6) ; NS2x p .01
Controls ( )np 48 22 (47.8) 22 (47.8) 4 (8.3)
a NS p not significant.
individuals and control mothers, nor was there any
increase in susceptible genotypes among the 47,XXX/
XXY mothers (table 1). However, among mothers of
trisomy 18 conceptuses, there was a significant increase
in the T allele ( ; ), and a significant2x p 6.10 P ! .05
increase in the proportion of susceptible (i.e., CT or TT)
genotypes by comparison with controls ( ;2x p 5.00
).P ! .05
At Cleveland, the maternal allele frequencies and
genotypic distributions were virtually identical for the
combined trisomy data set ( ) as for the controlsnp 158
(table 2). Further, there was no evidence for significant
deviations from the controls for any of the individual
trisomies.
MTRR:AtWessex, the maternal allele frequencies and
genotypic distributions were very nearly the same for the
47,XXX/XXY individuals as for the controls (table 3).
Similarly, there were no obvious differences between
mothers of trisomy 18 conceptuses and controls.
At Cleveland, values for the combined trisomy data
set were almost the same as those for controls (table 4).
Among individual trisomies, there was a nonsignificant
increase in mutant GG homozygotes among mothers of
trisomy 13 conceptuses, but there were no obvious dif-
ferences from control individuals for any of the other
trisomies.
Taken together, these data provide little support for a
major effect of maternal polymorphisms in the folate
pathway on humanmeiotic nondisjunction. AtMTHFR,
values for 47,XXX/XXY individuals and for sponta-
neously aborted trisomies were little different from those
of controls. Similarly, at MTRR none of the categories
of trisomies showed significant differences from con-
trols; indeed in most instances the case and control val-
ues were remarkably alike. However, one significant
association was identified, involving an increase in
MTHFR susceptible genotypes among mothers of tri-
somy 18 conceptuses. This may indicate an effect of
MTHFR variants on chromosome 18 nondisjunction, or
it may be a fortuitous observation reflecting the relatively
small number of cases yet studied and/or the number of
statistical comparisons that we conducted. Further anal-
yses will be required to confirm or refute this association.
With the exception of MTHFR and trisomy 18, we
observed no link between folate-pathway polymor-
phisms and any of the trisomies analyzed in the present
report. These results contrast with the previously re-
ported results for trisomy 21 (James et al. 1999; Hobbs
et al. 2000), which implied a substantial contribution of
both maternal MTHFR and MTRR polymorphisms to
chromosome 21 nondisjunction. Although the reasons
for this discrepancy are not yet clear, we can think of
several possible explanations:
First, it could be that there are significant differences
between the study populations (e.g., with the maternal
age distribution of our cases being different from that
in the previous studies) or in the meiotic origins of the
trisomies (e.g., with one data set involving meiosis I [MI]
errors and the other involving meiosis II [MII] errors).
However, in our data set, we found no evidence for
maternal age-related alterations in genotype frequencies
at either MTHFR or MTRR; thus, it seems unlikely that
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Table 3
Maternal MTRR Polymorphisms in Maternally Derived Cases of Sex Chromosome
Trisomy or Trisomy 18 and in Control Individuals
STUDY POPULATION







47,XXX or XXY ( )np 98 31 (31.6) 46 (46.9) 21 (21.4) ; NS2x p .26
Trisomy 18 ( )np 44 13 (29.5) 25 (56.8) 6 (13.6) ; NS2x p 1.99
Controls ( )np 56 17 (30.4) 25 (44.6) 14 (25.0) …
a NS p not significant.
Table 4
Maternal MTRR Polymorphisms in Maternally Derived Cases of Trisomies
2, 7, 10, 13, 14, 15, 16, or 22 and in Control Individuals
STUDY POPULATION








2 1 6 3 ; NS2x p 0.54
7 1 5 1 ; NS2x p 0.12
10 0 3 2 ; NS2x p 1.11
13 8 9 9 ; NS2x p 2.00
14 1 7 0 ; NS2x p 1.88
15 2 9 5 ; NS2x p 0.93
16 16 35 15 ; NS2x p 0.16
22 2 13 1 ; NS2x p 1.56
Total ( )np 154 31 (20.1) 87 (56.5) 36 (23.4) x2p0.29; NS
Controls ( )np 46 11 (23.9) 26 (56.5) 9 (19.6) …
a NS p not significant.
factors such as maternal age are the reason for the dis-
crepancy. Further, we found no evidence of an associ-
ation between genotype and the stage of origin of tri-
somy, since the genotypic distributions were similar for
MI- and MII-derived cases. Specifically, for MTHFR the
distribution of CC, CT, and TT genotypes was .48, .45
and .07 for MI-derived cases ( ) and .41, .45,np 148
and .14 for MII-derived cases ( ); for MTRR thenp 66
distribution of AA, AG, and GG genotypes was .28, .54,
and .18 for MI trisomies ( ) and .25, .49, andnp 152
.26 for MII trisomies ( ). Thus, we think it im-np 68
probable that this is the source of the difference.
Second, the discrepancy could be attributable to dif-
ferences in gene-nutrition interactions between the pre-
sent and previous study populations. Cellular methyla-
tion reactions involving MTHFR and MTRR require
folate and B12, respectively (Hobbs et al. 2000); thus,
the adverse consequences of the MTHFR and MTRR
variants—including the risk of neural tube defects and,
possibly, the risk of meiotic nondisjunction—are highly
dependent on nutritional status and will be maximized
by inadequate nutritional levels of folate or B12. Con-
sequently, any systematic differences in nutritional status
between study populations will complicate interstudy
comparisons. Because the nutritional status of mothers
in our study was not ascertained, we cannot eliminate
this as a explanation for the differences.
Third, it could be that the effect of polymorphisms at
MTHFR orMTRR is restricted to certain chromosomes,
including chromosome 21, and that we either studied
the “wrong” chromosomes or had too few data on those
chromosomes that are affected by these polymorphisms.
Consistent with this possibility, we identified an effect
for chromosome 18, with a sample size of 44. Further,
for several of the other autosomes (e.g., chromosomes
2, 7, 10, 14, and 22) !20 cases were available for anal-
ysis; thus, for these trisomies, even large effects would
have been difficult to detect. Nevertheless, we might ex-
pect that the pooled data from acrocentric trisomies 13,
14, 15, and 22 would display an effect similar to that
reported for trisomy 21—after all, available data indi-
cate little difference in maternal age patterns or in the
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mechanism of origin of nondisjunction among human
acrocentric trisomies (Hassold and Chiu 1985; Zaragoza
et al. 1994). However, for both MTHFR and MTRR,
the pooled data from trisomies 13, 14, 15, and 22 were
virtually identical to those from controls (tables 3 and
4). Thus, if there is an effect of folate polymorphisms
on acrocentric trisomies, it may well be restricted to
trisomy 21.
Fourth, it could be that the effect of the MTHFR and/
or MTRR polymorphisms is linked to the survival of
the trisomic conceptus. For example, the MTHFR
677CrT allele might be in linkage disequilibrium with
alleles that promote fetal survival (e.g., involving a
nearby locus that encodes a placental protein). If so, we
might expect increased survival of T allele–carrying tri-
somy 21 fetuses, with CC homozygotes being over-
represented among spontaneously aborted trisomy 21
conceptuses. The present data set does not allow us to
formally examine the possibility of differential selection
for the trisomies that we investigated. That is, whereas
we studied both spontaneously aborted and live-born
trisomies, for most categories of trisomy, only live-born
conceptuses (e.g., for the sex-chromosome trisomies) or
spontaneous abortions (e.g., for all autosomal trisomies
other than trisomy 18) were available for analysis. Nev-
ertheless, it should be relatively easy to examine this
question for trisomy 21, for which it is possible to obtain
case material from both live-born and spontaneously
aborted conceptuses.
Finally, it could be that the previous results on trisomy
21 were fortuitous and that maternal folate polymor-
phisms have little, if any, independent effect on meiotic
nondisjunction in humans. The absence of a demon-
strable familial component to human nondisjunction
(e.g., Sayee and Thomas 1998)—expected if folate var-
iants are a significant causative agent—and the absence
of significant racial variation in nondisjunction frequen-
cies (Hassold et al. 1980) are consistent with this con-
clusion. Further, two recent analyses of trisomy 21 sug-
gest that this may, indeed, be the case. That is, in an
analysis of 177 mothers of trisomy 21 conceptuses in
which the extra chromosome 21 was known to be ma-
ternally derived, Petersen et al. (2000) were unable to
demonstrate an increase in MTHFR mutations by com-
parison with controls. Further, in a similar analysis of
MTHFR in 85 mothers of individuals with DS, Chad-
efaux-Vekemans et al. (in press) found no difference be-
tween case and control subjects. Thus, the results of these
analyses provide little evidence that maternal folate-
pathway polymorphisms influence the risk of chromo-
some 21 nondisjunction. Nevertheless, our observation
of a significant association between MTHFR variants
and trisomy 18 and the previous links betweenMTHFR
and/or MTRR and trisomy 21 cannot be summarily dis-
missed and may indicate chromosome-specific effects.
The extraordinary clinical importance of such effects, if
proven, make it essential that additional analyses now
be conducted to confirm or refute the association.
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